Dextromethorphan Market Share

  • Report ID: 4078
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Dextromethorphan Market Share

North American Market Forecast   

North America industry is likely to dominate majority revenue share by 2037.The growth of the market can be attributed majorly to the increasing cases of bronchitis and bronchial asthma in the region. According to the data from the Centers for Disease Control and Prevention (CDC), 46.3 individuals out of every 100,000 population die due to chronic lower respiratory diseases in the U.S. Furthermore, as per a research paper by the National Library of Medicine, it is estimated that 5% of the population of North America reports an episode of acute bronchitis every year, accounting for more than 10 million hospital visits. Further, the presence of a strong healthcare network in the region, along with the availability of supportive policies by the regulatory bodies are also anticipated to contribute to market growth in the region. In addition, the region's expanding healthcare industry and rising healthcare expenditure are also anticipated to expand the size of the market during the forecast period.

APAC Market Statistics

On the other hand, the market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing cases of asthma, bronchitis, and cough along with the rising geriatric population in the region. Also, the high level of pollution and recent urbanization are other factors that are anticipated to fuel revenue generation of the market in the region in the upcoming years.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4078
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of dextromethorphan is estimated at USD 443.42 million.

The dextromethorphan market size was valued at USD 413.78 million in 2024 and is set to exceed USD 724.23 million by 2037, registering over 4.4% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of severe cough and other diseases will fuel the market growth.

North America industry is likely to dominate majority revenue share by 2037, due to increasing cases of bronchitis and bronchial asthma in the region.

The major players in the market are AstraZeneca PLC, FibroGen, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Sunovion Pharmaceuticals Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample